Episode 2

Hey there, and welcome to the very first episode of "Beyond the Scan"! I'm Jackie, your host, and I'm so glad you're tuning in today — it's April 4th, and we're officially kicking things off.

Now before we jump into the headlines, I just want to tell you a little bit about what this show is all about.

"Beyond the Scan" is your new go-to source for the latest breakthroughs, trends, and innovations in healthcare technology — with a special focus on imaging and Radiology. Every other week, I'll be here sharing the top stories and explaining what they actually mean for the future of medicine.

You can always find new episodes at beyondthescan.io, so be sure to bookmark it.

This innovative news show is proudly sponsored by RadiologyJobs.com — the premiere job board helping radiologists connect with real opportunities all across the U.S. If you're looking for your next role or just curious what's out there, RadiologyJobs.com is where you want to start.

Now, let's talk about what's on today's radar:

I've got some really exciting stories to share with you today! First, we'll be discussing the FDA approving the first new antibiotic class for UTIs in nearly 30 years. Then, we'll explore MD Anderson and UT Austin launching a $120 million cancer research accelerator. Next, we'll dive into a study revealing limitations in AI-powered ambient clinical documentation. And finally, we'll wrap up with the surge in spectral CT adoption following a Medicare reimbursement update. I'm really excited to dive into these stories with you because they're all showing us where healthcare is headed. I think you'll be particularly interested in our main story about that new antibiotic, which I found absolutely fascinating when I was researching for today's episode.

So, let's get into it! You know what's really interesting? The FDA just approved a brand-new antibiotic class for urinary tract infections, and it's been nearly three decades since we've seen anything like this! The drug is called gepotidacin, or as it's marketed, Blujepa, and it's specifically targeted at uncomplicated UTIs in women and girls aged 12 and older.

Isn't that amazing? We've been battling these pesky infections for so long, and with growing antimicrobial resistance, having a new option is a big deal. This new antibiotic works against Gram-negative bacteria, which are often the culprits behind UTIs. During trials, gepotidacin showed over 93% efficacy, which is really comparable to nitrofurantoin, that commonly prescribed antibiotic we've relied on for years, which clocked in at around 94%.

What I find particularly striking is that around 30% of recurrent UTI cases now show some level of antibiotic resistance. So, having a fresh approach could be a game changer for so many patients who have struggled with these infections. Imagine the relief for those who have had to deal with recurrent UTIs!

While we're talking about medical breakthroughs... MD Anderson and UT Austin just launched a $120 million initiative called the Collaborative Accelerator for Transformative Research Endeavors, or CARE for short. This partnership aims to fast-track oncology projects that could really change the landscape of cancer treatment.

How cool is that? They're focusing on some cutting-edge areas like AI-guided radiotherapy planning and nanoparticle drug delivery systems. Just think about how AI tools could help in making treatment plans more precise and tailored to individual patients. Plus, they're looking into CRISPR-based biomarkers for early detection—talk about revolutionary!

By leveraging UT Austin's engineering prowess along with MD Anderson's clinical trial infrastructure, they're hoping to reduce development timelines by about 40%. That's huge! It means potentially getting new treatments into the hands of patients much faster.

Speaking of innovations... I also wanted to tell you about a study that caught my attention regarding AI-powered ambient clinical documentation. Researchers at the Peterson Health Technology Institute analyzed several leading scribe platforms, and the results were pretty mixed.

They found that while these tools could save a couple of hours each week on documentation time—about 2.5 hours, to be exact—roughly two-thirds of clinicians reported feeling an increased cognitive load when interacting with patients. Can you imagine trying to juggle patient engagement while also managing the tech? It's a lot!

The report really emphasized the need for better integration with electronic health records and more thorough validation of these tools' accuracy, especially in multi-specialty settings. It's a reminder that while technology can be a great ally... we still need to ensure it's genuinely assisting us rather than adding to the complexities of patient care.

This brings us to an interesting development in imaging technology... There's been a surge in the adoption of spectral CT following a recent update in Medicare reimbursement policy. The Centers for Medicare & Medicaid Services expanded coverage for photon-counting CT in pulmonary and oncology applications, and guess what? This has led to nearly one-third growth in installations just in the first quarter of 2025!

This represents a significant increase in adoption, which is remarkable given how new the technology is. This technology—and I really want to emphasize this—can differentiate between five contrast agents simultaneously, which can really streamline the imaging process. You know how patients often have to go through repeat scans? Well, this advancement has been shown to reduce those by about 65% in liver studies. That's not just a win for efficiency; it's a win for the patients who avoid unnecessary procedures.

Early adopters of the spectral CT are also reporting 28% faster turnaround times for complex cancer staging. Imagine how that could improve patient care! Quicker results mean quicker decisions and, potentially, better outcomes.

Well, that's all we have for today's episode of "Beyond the Scan." I've really enjoyed sharing these developments with you.

If you found today's discussion helpful, I'd love it if you'd subscribe and share with your colleagues. And hey, swing by our website at beyondthescan.com where we've got some great additional resources on these topics.

I'll be back in two weeks with more exciting updates. This is Jackie signing off, and remember—what we do really does make a difference in people's lives every day. Take care!